Chengdu huasun technology group Inc. , LTD. (SHE:000790)
China · Delayed Price · Currency is CNY 4.110
-0.090 (-2.14%)
Sep 10, 2026, 3:04 PM CST
SHE:000790 Revenue
Chengdu huasun technology group Inc. , LTD. had revenue of 123.61M CNY in the quarter ending June 30, 2026, a decrease of -24.98%. This brings the company's revenue in the last twelve months to 486.70M, down -30.25% year-over-year. In the year 2025, Chengdu huasun technology group Inc. , LTD. had annual revenue of 545.50M, down -36.86%.
Revenue (ttm)
486.70M
Revenue Growth
-30.25%
P/S Ratio
5.38
Revenue / Employee
669.47K
Employees
727
Market Cap
2.62B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 545.50M | -318.48M | -36.86% |
| Dec 31, 2024 | 863.98M | -139.40M | -13.89% |
| Dec 31, 2023 | 1.00B | 130.27M | 14.92% |
| Jan 1, 2023 | 873.10M | -81.58M | -8.55% |
| Jan 1, 2022 | 954.69M | 195.38M | 25.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Fengyuan Pharmaceutical | 3.50B |
| Shaanxi Panlong Pharmaceutical Group | 989.42M |
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 849.67M |
| Zhejiang Shengda Bio-Pharm | 832.86M |
| Baotou Dongbao Bio-Tech Co.,Ltd | 790.94M |
| Jiangxi Synergy Pharmaceutical | 784.40M |
| Chongqing Jiheng Pharmaceutical | 654.22M |
| Hainan Huluwa Pharmaceutical Group | 634.04M |